- Home
- CALC vs SDST Comparison
CALC vs SDST Comparison
Compare CALC & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- SDST
- Stock Information
- Founded
- CALC 2011
- SDST 2022
- Country
- CALC United States
- SDST United States
- Employees
- CALC N/A
- SDST N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- SDST Blank Checks
- Sector
- CALC Health Care
- SDST Finance
- Exchange
- CALC Nasdaq
- SDST Nasdaq
- Market Cap
- CALC 32.4M
- SDST 37.0M
- IPO Year
- CALC N/A
- SDST N/A
- Fundamental
- Price
- CALC $3.80
- SDST $0.53
- Analyst Decision
- CALC Strong Buy
- SDST Buy
- Analyst Count
- CALC 2
- SDST 2
- Target Price
- CALC $14.50
- SDST $1.70
- AVG Volume (30 Days)
- CALC 133.2K
- SDST 26.0M
- Earning Date
- CALC 08-11-2025
- SDST 08-15-2025
- Dividend Yield
- CALC N/A
- SDST N/A
- EPS Growth
- CALC N/A
- SDST N/A
- EPS
- CALC N/A
- SDST N/A
- Revenue
- CALC N/A
- SDST N/A
- Revenue This Year
- CALC N/A
- SDST N/A
- Revenue Next Year
- CALC N/A
- SDST $246.67
- P/E Ratio
- CALC N/A
- SDST N/A
- Revenue Growth
- CALC N/A
- SDST N/A
- 52 Week Low
- CALC $1.42
- SDST $0.14
- 52 Week High
- CALC $5.97
- SDST $17.62
- Technical
- Relative Strength Index (RSI)
- CALC 73.90
- SDST N/A
- Support Level
- CALC $3.37
- SDST N/A
- Resistance Level
- CALC $4.26
- SDST N/A
- Average True Range (ATR)
- CALC 0.41
- SDST 0.00
- MACD
- CALC 0.21
- SDST 0.00
- Stochastic Oscillator
- CALC 82.80
- SDST 0.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).